Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 12-Lead ECG Clear all
Completed Not applicable Interventional

The Influence of Cardiorespiratory Fitness on Firefighter Cardiovascular Health Under Exercise Conditions

NCT04514354
View directory record Official record
Conditions
Cardiovascular Diseases, Post-Exercise Hypotension
Interventions
GEST
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 3, 2026, 2:35 AM EDT
Completed No phase listed Observational

Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction

NCT03037229
View directory record Official record
Conditions
STEMI
Interventions
Smartphone ECG, Standard 12-lead ECG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

NCT06641362
View directory record Official record
Conditions
Bradycardia, Heart Failure, Ventricular Dysfunction
Interventions
Ultra High Frequency Electrocardiogram (UHF-ECG)
Device
Lead sponsor
VDI Technologies
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Avondale, Arizona • Mesa, Arizona • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 3, 2026, 2:35 AM EDT
Active, not recruiting Not applicable Interventional

Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial

NCT05784766
View directory record Official record
Conditions
Cancer
Interventions
30-second ECG using the Kardia Mobile, routine care
Diagnostic Test · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 90 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Not applicable Interventional

AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

NCT06123130
View directory record Official record
Conditions
Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia
Interventions
Vectorcardiography (VECG)
Device
Lead sponsor
HeartBeam, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Atlanta, Georgia • Tucker, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Electrocardiogram Clinical Validation Study

NCT03492554
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
1-Lead ECG, 12-Lead ECG
Other · Device
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • The Villages, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 3, 2026, 2:35 AM EDT
Active, not recruiting Not applicable Interventional

Cardiac Outcomes With Near-Complete Estrogen Deprivation

NCT05309655
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications
Interventions
Adenosine Stress Cardiac Magnetic Resonance Imaging, Electrocardiogram, Computed Tomography Angiogram, Laboratory Testing, Quality of Life Survey
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Durham, North Carolina • Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

NCT04563845
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Not applicable Interventional Results available

Home Telemonitoring In Patients After Myocardial Infarction

NCT04664881
View directory record Official record
Conditions
Myocardial Infarction, Heart Attack
Interventions
SmartHeart Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 3, 2026, 2:35 AM EDT
Active, not recruiting No phase listed Observational

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT06290570
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
12-Lead ECG, Apple Smart Watch Single Lead ECG, AliveCor KardiaMobile 6-Lead ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG

NCT00998842
View directory record Official record
Conditions
Healthy
Interventions
Recom Model 100, GE 5000 ECG Monitor System
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Sep 3, 2026, 2:35 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia

NCT01746940
View directory record Official record
Conditions
Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes, of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Recruiting Phase 4 Interventional

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

NCT07178145
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Interventions
GLP-1RA
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 3, 2026, 2:35 AM EDT
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 3, 2026, 2:35 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 3, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

Detection of Atrial Fibrillation Using PPG From Smartphone Cameras

NCT07779213
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
12 Lead ECG is compared to a smartphone based PPG
Diagnostic Test
Lead sponsor
Happitech BV
Industry
Eligibility
22 Minutes and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Jonesboro, Arkansas • Littleton, Colorado • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Further Study of AFGen1 Clinical Performance

NCT06335498
View directory record Official record
Conditions
Atrial Fibrillation, Afib, ECG
Interventions
ECG co-measurement, Periodic ECG triggered measurement
Device
Lead sponsor
TriVirum, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Not applicable Interventional

A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

NCT04002531
View directory record Official record
Conditions
Quality of Life, Renal Insufficiency, Cardiac Event
Interventions
General and Neurological examination, Vital signs, 12 lead electrocardiogram, Echocardiogram, Blood draw, Urine collection, 2-hour Holter Monitor, Brief Pain Inventory questionnaire, Quality of Life questionnaire
Other · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2010 · Synced Sep 3, 2026, 2:35 AM EDT
Terminated Not applicable Interventional

Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

NCT05465655
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
ECG monitoring for Conduction Disturbances
Other
Lead sponsor
Cara Medical Ltd
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 3, 2026, 2:35 AM EDT